Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Certain pre-existing conditions may highly increase a patient's risk of dying from COVID-19

A large, international study of COVID-19 patients confirmed that cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease, stroke and cancer can increase a patient's risk of dying from the virus.

8 Oct 2020

Pre-existing conditions can increase patient's risk of dying from COVID-19

8 Oct 2020

Study fails to establish independent risk factors for SARS-COV-2 infection in HIV patients

As the COVID-19 pandemic continues to spread worldwide, a new study published in the International Journal of Infectious Diseases in September 2020 reports that people with HIV infection are not at greater risk of COVID-19 compared to the general population.

5 Oct 2020

Study unravels how lysosomal damage response pathways prevent kidney injury

Human cells need to work like well-oiled machines to keep our bodies running as they should. Waste products such as misfolded proteins, damaged cellular components, and carbohydrates get in the way and must be quickly disposed of.

28 Sep 2020

Study finds new treatment approach for patients with salt sensitive hypertension

High blood pressure (hypertension) affects one in two U.S. adults and can cause hardening and thickening of the arteries (atherosclerosis), which can lead to heart attacks, strokes or other complications including chronic kidney disease.

28 Sep 2020

Newer Type 2 diabetes medications could reduce kidney, heart disease risks

Two newer groups of medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with chronic kidney disease (CKD) and heart disease.

28 Sep 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020

Shorter time from COVID-19 symptom onset to hospitalization linked to disease severity, death

New research presented at this week's ESCMID Conference on Coronavirus Disease (ECCVID, held online) shows that a shorter time from symptom onset to hospitalization is associated with more serious disease and death in patients with COVID-19.

26 Sep 2020

Study examines the disproportionate impact of COVID-19 on health care disparities

A new Viewpoint piece published online in the Annals of the American Thoracic Society examines the ways in which COVID-19 disproportionately impacts historically disadvantaged communities of color in the United States, and how baseline inequalities in our health system are amplified by the pandemic.

25 Sep 2020

Diabetes leads to drastic reduction in the kidney's potential to clean itself

The kidneys often become bulky and dysfunctional in diabetes, and now scientists have found that one path to this damage dramatically reduces the kidney's ability to clean up after itself.

22 Sep 2020

Phosphate binder drug does not reduce heart disease risk in people with chronic kidney disease

Following a large-scale clinical trial, researchers have found that lanthanum carbonate does not reduce the risk of cardiovascular disease developing in patients with chronic kidney disease.

14 Sep 2020

Why Black aging matters, too

Old. Chronically ill. Black. People who fit this description are more likely to die from COVID-19 than any other group in the country.

3 Sep 2020

Active lifestyle choices can lower the risk of chronic kidney disease

Active lifestyle choices such as eating vegetables, exercising and quitting smoking can reduce the risk of chronic kidney disease, a new study led by researchers at Karolinska Institutet in Sweden and Griffith University in Australia, reports.

2 Sep 2020

Majority of U.S. COVID-19 fatalities had underlying medical conditions

Early on in the coronavirus disease (COVID-19) pandemic, there was little data on the virus and how it affects the body. As the virus spread across the globe, data showed that some people were at a higher risk of developing severe disease and dying from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

31 Aug 2020

SGLT2 inhibitors can slow CKD progression

850 million people worldwide are affected by chronic kidney disease (CKD) - a worrying figure, and one that continues to rise.

31 Aug 2020

DAPA-CKD trial shows dapagliflozin reduces risk of chronic kidney disease

Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalization and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes.

31 Aug 2020

Dialysis patients have higher risk for SARS-CoV-2 infection, study suggests

It's widely known that the causative agent for COVID-19, the SARS-CoV-2 virus, can spread rapidly among residents in nursing homes and other long-term care facilities, leading to high numbers of cases and deaths in a very vulnerable population.

25 Aug 2020

Antihypertensives improve COVID-19 survival rates

Previous studies have also linked hypertension to severe coronavirus disease (COVID-19). Now, a new study by researchers at the University of East Anglia's Norwich Medical School has found that the risk of severe COVID-19 and death was reduced for patients with high blood pressure who were taking Angiotensin-Converting Enzyme inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB).

24 Aug 2020

SARS-CoV-2 viral load predicts risk of death

As the coronavirus pandemic evolved, there have been many developments in testing for the SARS-CoV-2 viral load in patients. Now, a team of researchers at the Icahn School of Medicine at Mount Sinai, New York, has found that the SARS-CoV-2 viral load can predict mortality in patients with coronavirus disease (COVID-19).

13 Aug 2020

IRB Barcelona team receives ERC grant to develop new drugs against fibrosis

The team led by Manuel Serrano, ICREA researcher and Head of the Cellular Plasticity and Disease Lab at IRB Barcelona, has been awarded the Proof of Concept grant by the European Research Council.

31 Jul 2020